That was the reason that motivated Food and Drug Administration to grant accelerated approval to atezolizumab for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 (22). This evidence concerns the gene CD274 and triple-negative breast carcinoma.